Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 12 of 12 publications.

Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Davis KL, Ubieto A, Nagar S, Zhang AJ, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. A retrospective cohort study of treatment outcomes of adult patients with relapsed or Refractory Follicular Lymphoma (ReCORD-FL). Hemasphere. 2022 Jun 21;6(7):e745. doi: 10.1097/HS9.0000000000000745

Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS. Quality of life in adult and pediatric patients with tropomyosin receptor kinase fusion cancer receiving larotrectinib. Curr Probl Cancer. 2021 Dec;45(6):100734. doi: 10.1016/j.currproblcancer.2021.100734

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, Lopez C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-58. doi: 10.1016/S2468-1253(21)00110-2

Levy C, Bell T, Lyall M, Mamolo C, Neuhof A, Crawford R, Heyes A. The patient experience of multiple myeloma: symptoms and health-related quality of life. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):789.

Crawford R, Bell T, Levy C, Mamolo C, Lyall M, Neuhof A, Heyes A. The impact of COVID-19 on patient disease experience: insights from social media posts contributed by patients with multiple myeloma. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2).

Kortum KM, Nagar SP, Singh E, Davis KL, Lin PL. A multinational chart review of real-world treatment patterns and clinical outcomes in patients with relapsed/refractory multiple myeloma. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):466-7.

Lyall M, Heyes A, Bell T, Mamolo C, Neuhof A, Levy C, Crawford R. Multiple myeloma treatment decisions from the patient perspective. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):788.

Purser M, Gallagher M, Mladsi D, Weber JM, Andermariam B, Kaye JA, Chawla A. Development of key criteria for an economic model for a potentially curative one-time treatment for sickle cell disease and evaluation of published models with respect to these criteria. Hemasphere. 2020;p.1098-9.

Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D, Gnanasakthy A, Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3. Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.

Matanock A, Lu X, Derado G, Cuellar VM, Juliao P, Alvarez M, Lopez B, Munoz F, Thornton A, Patel JC, Lopez G, Reyes L, Arvelo W, Blackstock AJ, Lindblade KA, Roy SL. Association of water quality with soil-transmitted helminthiasis and diarrhea in Nueva Santa Rosa, Guatemala, 2010. J Water Health. 2018 Oct;16(5):724-36. doi: 10.2166/wh.2018.207

Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M. Comparison of olanzapine and risperidone in the EMBLEM study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep;25(5):257-63.

Pattanayak SK, Poulos C, Yang JC, Patil SR, Wendland KJ. Of taps and toilets: quasi-experimental protocol for evaluating community-demand-driven projects. J Water Health. 2009 Sep 1;7(3):434-51.